DROMOS DR/DR-A AND DROMOS SR/SR-B CARDIAC PACING SYSTEMS
Biotronik, Inc. · Decision date Oct 11, 1996
What did the FDA approve?
FDA approved PMA P950037 on October 11, 1996, for the DROMOS DR/DR-A and DROMOS SR/SR-B cardiac pacing systems from Biotronik, Inc. The approval statement describes rate adaptive pacing with these pulse generators as indicated for patients exhibiting chronotropic incompetence who would benefit from increased pacing rates concurrent with physical activity.
The source statement reports an intended patient population and functional purpose, not an independent demonstration of safety or clinical effectiveness. The record does not identify a supplement type or reason, so no relationship to a prior PMA scope change can be established from the supplied fields.
FDA approval order statement
RATE ADAPTIVE PACING WITH THE DROMOS DR AND DROMOS SR PULSE GENERATORS IS INDICATED FOR PATIENTS EXHIBITING CHRONOTROPIC INCOMPETENCE AND WHO WOULD BENEFIT FROM INCREASED PACING RATES CONCURRENT WITH PHYSICAL ACTIVITY
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Oct 11, 1996
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P950037
- Regulatory pathway
- Premarket approval application
- Applicant
- Biotronik, Inc.
- Product code
- DXY
- Decision code
- APPR
- Decision date
- Oct 11, 1996
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: implantable pacemaker Pulse-generator.
- Applicant
- Biotronik, Inc.
- Product code
- DXY
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P950037 received
Application receipt date recorded by FDA.
P950037 · FDA decision
APPR
P950037/S291 · Related supplement
PSW 2601.U, NEO 2601.U, Amvia Sky HF-T QP, Amvia Sky HF-T, Amvia Edge HF-T QP, Amvia Sky DR-T, Amvia Sky SR-T, Amvia Edg
P950037/S279 · Related supplement
Edora 8 DR-T 407145, Evity 8 DR-T 407146, Enitra 8 DR-T 407147, Enticos 8 DR-T 407148, Evity 6 DR-T 407149, Enitra 6 DR-
P950037/S296 · Related supplement
Edora 8 DR-T 407145; Evity 8 DR-T 407146; Enitra 8 DR-T 407147; Enticos 8 DR-T 407148; Evity 6 DR-T 407149; Enitra 6 DR-
P950037/S298 · Related supplement
Edora 8 DR-T, Evity 8 DR-T, Enitra 8 DR-T, Evity 6 DR-T, Enitra 6 DR-T, Edora 8 DR, Enitra 6 DR, Enticos 4 DR, Enticos
P950037/S289 · Related supplement
BIOexpress
P950037/S299 · Related supplement
Edora 8 DR-T, Evity 8 DR-T, Enitra 8 DR-T, Enticos 8 DR-T, Evity 6 DR-T, Enitra 6 DR-T, Edora 8 DR, Enitra 6 DR, Edora 8
P950037/S300 · Related supplement
Amvia Sky DR-T, Amvia Sky SR-T; Amvia Edge DR-T, Amvia Edge SR-T; Solvia Rise DR-T, Solvia Rise SR-T; Amvia Sky HF-T QP,
Timeline entries are records held by MedtechLedger for P950037. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P950037
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biotronik, Inc. | PMA supplement | Sep 17, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Sep 25, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 9, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 13, 2026 | FDA | |
BIOexpressP950037/S289 | Biotronik, Inc. | PMA supplement | Oct 16, 2026 | FDA |
| Biotronik, Inc. | PMA supplement | Oct 22, 2026 | FDA | |
| Biotronik, Inc. | PMA supplement | Oct 28, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Biotronik, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6024 Jean Rd., Lake Oswego, OR, 97035
Sources and methodology
- Original FDA record: P950037
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



